Key result
A novel SCN5A Q1000K mutation and multiple 3'UTR variants were identified in a Tunisian family with Brugada syndrome, demonstrating incomplete penetrance and suggesting that the disease is driven by a combination of genetic factors.
Observational
The identification of a novel SCN5A mutation and 3'UTR variants affecting microRNA binding in a Brugada syndrome family highlights the complex, multigenic nature of the disease involving both coding and regulatory regions.
Does not yet alter clinical management; hypothesis-generating for multigenic Brugada inheritance including 3'UTR variants.
Brugada syndrome (BrS) is a rare inherited cardiac arrhythmia associated with a high risk of sudden cardiac death (SCD) due to ventricular fibrillation (VF). BrS is characterized by coved-type ST-segment elevation in the right precordial leads (V1-V3) in the absence of structural heart disease. This pattern is spontaneous, or is unmasked by intravenous administration of Class I antiarrhythmic drugs. The SCN5A-encoded α-subunit of the NaV1.5 cardiac sodium channel has been linked to BrS, and mutations in SCN5A are identified in 15–30% of BrS cases. Genetic testing of BrS patients generally involves sequencing of protein-coding portions and flanking intronic regions of SCN5A, according to recent international guidelines. This excludes the regulatory untranslated regions (5’UTR and 3’UTR) from the routine genetic testing of BrS patients. We here screened the coding sequence, the flanking intronic regions as well as the 5’ and 3’UTR regions of SCN5A gene and further five candidate genes (GPD1L, SCN1B, KCNE3, SCN4B, and MOG1) in a Tunisian family diagnosed with Brugada syndrome. A new Q1000K mutation was identified on the SCN5A gene along with two common polymorphisms (H558R and D1819). Furthermore, multiple genetic variants were identified on the SCN5A 3’UTR, one of which is predicted to create additional microRNA (miRNAs) binding site for miR-1270. Additionally, we identified the hsa-miR-219a rs107822. No relevant coding sequence variant was identified in the remaining studied candidate genes. Although Q1000K is localized in the conserved binding site of MOG1 which predicts a functional consequence, this new mutation along with the additional variants were differentially distributed among the family members without any clear genotype-phenotype concordance. This gives extra evidences about the complexity of the disease and suggests that the occurrence and prognosis of BrS is most likely controlled by a combination of multiple genetic factors and exposures, rather than a single polymorphism/mutation. Most SCN5A polymorphisms were localized in non-coding regions hypothesizing an impact on the miRNA-target complementarities. In this regard, over-expression of miR-1270 led to a significant decrease of luciferase activity suggesting a direct role regulating SCN5A. Therefore, genetic variants that disrupt its binding affinity to SCN5A 3’UTR and/or its expression might cause loss of normal repression control and be associated to BrS.
No takes yet. Share an insight, caveat, or question.
Daimi et al. (2017) conducted an observational in Brugada syndrome. SCN5A genetic variants (Q1000K mutation and 3'UTR polymorphisms) vs. Healthy controls / non-carriers was evaluated on Identification of genetic variants associated with Brugada syndrome. A novel SCN5A Q1000K mutation and multiple 3'UTR variants were identified in a Tunisian family with Brugada syndrome, demonstrating incomplete penetrance and suggesting that the disease is driven by a combination of genetic factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: